Cellectis S.A. - Product Pipeline Review - 2014

Published: Dec, 2014 | Pages: 41 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Cellectis S.A. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Cellectis S.A. - Product Pipeline Review - 2014', provides an overview of the Cellectis S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cellectis S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Cellectis S.A. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Cellectis S.A.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Cellectis S.A.'s pipeline products

Reasons to buy

- Evaluate Cellectis S.A.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Cellectis S.A. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Cellectis S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Cellectis S.A. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cellectis S.A.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Cellectis S.A. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Cellectis S.A. Snapshot 6
Cellectis S.A. Overview 6
Key Information 6
Key Facts 6
Cellectis S.A. - Research and Development Overview 7
Key Therapeutic Areas 7
Cellectis S.A. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Cellectis S.A. - Pipeline Products Glance 14
Cellectis S.A. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Cellectis S.A. - Drug Profiles 16
UCART-123 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
UCART-19 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Cell Therapy for Cancer 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Gene Therapy for Hemophilia 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
S-2 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
S-3 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
S-4 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
S-5 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
S-6 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
S-7 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Stem Cell Therapy for Diabetes 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
UCART-33 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
UCART-38 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
UCART-5T4 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
UCART-BCMA 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
UCART-EgfrVIII 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
UCARTCS-1 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Cellectis S.A. - Pipeline Analysis 33
Cellectis S.A. - Pipeline Products by Target 33
Cellectis S.A. - Pipeline Products by Molecule Type 34
Cellectis S.A. - Pipeline Products by Mechanism of Action 35
Cellectis S.A. - Recent Pipeline Updates 36
Cellectis S.A. - Dormant Projects 38
Cellectis S.A. - Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Tables
Cellectis S.A., Key Information 6
Cellectis S.A., Key Facts 6
Cellectis S.A. - Pipeline by Indication, 2014 9
Cellectis S.A. - Pipeline by Stage of Development, 2014 10
Cellectis S.A. - Monotherapy Products in Pipeline, 2014 11
Cellectis S.A. - Partnered Products in Pipeline, 2014 12
Cellectis S.A. - Partnered Products/ Combination Treatment Modalities, 2014 13
Cellectis S.A. - Preclinical, 2014 14
Cellectis S.A. - Discovery, 2014 15
Cellectis S.A. - Pipeline by Target, 2014 33
Cellectis S.A. - Pipeline by Molecule Type, 2014 34
Cellectis S.A. - Pipeline Products by Mechanism of Action, 2014 35
Cellectis S.A. - Recent Pipeline Updates, 2014 36
Cellectis S.A. - Dormant Developmental Projects,2014 38
Cellectis S.A., Subsidiaries 39